ARWR Price Prediction Next Week
Analysis and Insights
News Sentiment and Recent Developments:
Arrowhead Pharmaceuticals (ARWR) has recently announced positive topline results from Part 2 of a Phase 1/2 study for ARO-C3, showing significant reductions in complement activity and proteinuria in patients with IgA nephropathy. This has bolstered confidence in the company's complement disease franchise and its potential for future success. Despite this, ARWR's stock fell 8.72% following the announcement, possibly due to profit-taking or market expectations.
H.C. Wainwright maintains a Buy rating and an $80 price target for ARWR, citing the blockbuster potential of ARO-C3.
Technical Analysis:
The stock is currently trading at $15.50, with key technical indicators suggesting potential upside:
- RSI (14): 30.52, indicating oversold conditions and a potential rebound.
- MACD: -1.17, showing a bearish trend but nearing a potential crossover.
- Fibonacci Levels: Resistance at $16.46 (R1) and support at $14.44 (S1).
Price Prediction and Recommendation:
Based on the oversold RSI, positive news sentiment, and approaching Fibonacci support levels, ARWR is likely to rebound next week. The stock is expected to test the Fibonacci resistance level of $16.46.
Prediction:
- Target Price: $16.46
- Recommendation: Buy
- Stop-Loss: $14.44
This prediction is based on technical indicators and positive news sentiment.
ARWR Similar Chart Price Prediction
The price of ARWR is predicted to go up 2.76%, based on the high correlation periods with BLFS. The similarity of these two price pattern on the periods is 97.81%.
ARWR
BLFS
Up: 2.76%Similarity: 97.81%
ARWR Revenue Forecast
ARWR EPS Forecast
ARWR FAQs
What is ARWR revenue forecast for next quarter？
What is ARWR eps forecast for next quarter？
ARWR Analyst's Forecast
William Pickering
Bernstein
Hold
2024-11-29
Price Target
$27 → $24
Downside
-7.8%
Bernstein lowered the firm's price target on Arrowhead (ARWR) to $24 from $27 and keeps a Market Perform rating on the shares. The company's fiscal Q4 update centered primarily on the large collaboration deal announced with Sarepta (SPRT) and implications for its own strategy going forward, the analyst tells investors in a research note. The firm takes a "very positive view" on the deal, both for its transformational impact on Arrowhead's cash position and the greater focus it will bring to the wholly-owned pipeline. The one downside about the deal is that" it dries up the catalyst path somewhat and may lead to ARWR being put in the funding short bucket," contends Bernstein.
Edward Tenthoff
Piper Sandler
Buy
2024-11-27
Price Target
$62 → $45
Upside
+72.48%
Shawn Egan
Citigroup
Hold
2024-11-27
Price Target
$27 → $26
Downside
-0.34%
